Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rituximab biosimilar - Genor Biopharma

Next Previous
Drug Profile

Rituximab biosimilar - Genor Biopharma

Alternative Names: GB-241

Latest Information Update: 28 Sep 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genor Biopharma
  • Developer Genor Biopharma; Nanjing Yoko Biomedical
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diffuse large B cell lymphoma
  • No development reported Non-Hodgkin's lymphoma

Most Recent Events

  • 28 Sep 2022 Phase III development is still ongoing for Diffuse large B cell lymphoma (First-line therapy, Combination trial) in China (IV) (Genor Biopharma pipeline, September 2022)
  • 28 Nov 2019 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma in China (IV)
  • 20 May 2019 Nanjing Yoko Biomedical completes a phase I trial in Non-Hodgkin's lymphoma in China (IV) (NCT03003039)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top